Tuesday, September 18, 2012 8:19:07 PM
http://www.cancer.gov/ncicancerbulletin/091812/page3#b
New Drug Improves Survival in Patients with Advanced Lung Cancer
Patients with advanced lung cancer who received the drug bavituximab lived twice as long as trial participants who did not receive the drug. These results , from a phase II trial, were presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology . Peregrine Pharmaceuticals, Inc., the drug’s manufacturer, sponsored the trial.
Bavituximab is a monoclonal antibody that targets a molecule called phosphatidylserine (PS) that is found in the membranes of cells throughout the body, including those that line blood vessels. In normal cells, PS is restricted to the inside of cell membranes, where it is inaccessible to antibodies. Under certain conditions, like those found in the stressful tumor microenvironment, PS moves to the outer surface of the cell membrane, explained the study’s principal investigator, Dr. David Gerber of the University of Texas Southwestern Medical Center. In the case of tumor blood vessels, this means that PS is exposed and accessible to antibodies in the blood.
Laboratory studies have shown that bavituximab can trigger the destruction of tumor blood vessels. The drug may also work by harnessing the immune system. Tumors supplied by blood vessels with exposed PS can evade an immune response. That’s because exposed PS normally marks cells that are in the process of dying, so the immune system ignores them. The researchers hoped to learn whether bavituximab, by binding to PS, would signal to the immune system to attack tumor blood vessels with exposed PS, explained Dr. Gerber.
In the double-blind, placebo-controlled trial, the researchers randomly assigned 117 patients to one of three treatment groups: docetaxel (Taxotere) plus placebo, docetaxel plus a low dose of bavituximab, or docetaxel plus a higher dose of bavituximab. All patients had previously received initial chemotherapy. The trial was unblinded 18 months after the first patient was enrolled.
The results showed differences in tumor shrinkage (15 and 18 percent of patients in the low and high bavituximab groups had their tumors shrink, versus 8 percent of those receiving docetaxel plus placebo) and progression-free survival (about 4.5 months in the two bavituximab arms, versus 3 months with docetaxel plus placebo).
The greatest differences were for overall survival; patients receiving docetaxel plus placebo lived an average of 5.6 months from the start of treatment, whereas patients receiving docetaxel plus the low or high dose of bavituximab lived for an average of 11 and 13 months, respectively.
These survival differences are not likely due to differences in treatment received after the trial, Dr. Gerber noted. Seeing a larger improvement in overall survival than in progression-free survival is unusual for drugs that target cancer cells directly, he added. Because the improvement in survival with bavituximab “is persistent and most pronounced after a few months,” that suggests that the therapeutic benefit may be caused, at least in part, by an immune response, he said.
The researchers are planning a phase III trial of bavituximab in a larger group of lung cancer patients. Bavituximab is also being tested in combination with other treatments in patients with breast, rectal, liver, and prostate cancer.
Recent CDMO News
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 12:56:02 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/08/2024 09:32:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:56:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:55:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:53:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:51:57 AM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM